RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer
- 1 April 2008
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Review of Anticancer Therapy
- Vol. 8 (4), 625-632
- https://doi.org/10.1586/14737140.8.4.625
Abstract
Hereditary medullary thyroid carcinoma (MTC) is caused by specific autosomal dominant gain-of-function mutations in the RET proto-oncogene. Genotype–phenotype correlations exist that help predict the presence of other associated endocrine neoplasms as well as the timing of thyroid cancer development. MTC represents a promising model for targeted cancer therapy, as the oncogenic event responsible for initiating malignancy has been well characterized. The RET proto-oncogene has become the target for molecularly designed drug therapy. Tyrosine kinase inhibitors targeting activated RET are currently in clinical trials for the treatment of patients with MTC. This review will provide a brief overview of MTC and the associated RET oncogenic mutations, and will summarize the therapies designed to strategically interfere with the pathologic activation of the RET oncogene.Keywords
This publication has 67 references indexed in Scilit:
- Medullary thyroid cancer: therapeutic targets and molecular markersCurrent Opinion in Oncology, 2007
- Inhibition of carcinoma cell-derived VEGF reduces inflammatory characteristics in xenograft carcinomaInternational Journal of Cancer, 2006
- Prognosis of medullary thyroid carcinomaCancer, 2006
- TrastuzumabDrugs, 2006
- Neutralizing Aptamers from Whole-Cell SELEX Inhibit the RET Receptor Tyrosine KinasePLoS Biology, 2005
- Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitorsOncogene, 2004
- RET and neuroendocrine tumorsCancer Letters, 2004
- Generation and characterization of novel monoclonal antibodies to the Ret receptor tyrosine kinaseBiochemical and Biophysical Research Communications, 2002
- MEN2A-RET-induced cellular transformation by activation of STAT3Oncogene, 2001
- Familial medullary thyroid carcinoma without associated endocrinopathies: A distinct clinical entityBritish Journal of Surgery, 1986